Stimulation of osteoblast activity by homocysteine.
Homocysteine (HCY) has recently been linked to fragility fractures. Moreover, HCY activates osteoclasts. Little is known about the effect of HCY on activity of human osteoblasts (OBs). We hypothesized that HCY decreases the activity of OBs. Osteoblasts obtained from trabecular human bone specimens of eight donors were cultured with conditioned medium. Culture medium was adjusted to 0, 100, 500, 1000 and 2000 microM HCY. After 14 days alkaline phosphatase (AP) activity, pro-collagen type I N-terminal peptide (PINP) and osteocalcin (OC) secretion in the supernatant were measured. After 20 days the formation of mineralized matrix was analyzed. HCY-stimulated AP activity gradually (100 microM HCY: 118%, P=0.006; 500 microM HCY: 125%, P<0.001). At 1000 and 2000 microM HCY the increase of AP activity was reversible (1000 microM HCY: 106%, P=0.317; 2000 microM HCY: 102%, P<0.737). The PINP secretion was also stimulated by HCY reaching a maximum of 260+/-154 microg/l at 500 micromol/l versus 205+/-94 microg/l in controls. After 20 days of culture the formation of bone matrix was increased at 100 and 500 microM HCY. OC secretion was not significantly changed. The results of the present study consistently demonstrate a moderate stimulation of primary human OB activity by increasing concentrations of HCY. However, the magnitude of this effect seems to be less pronounced than recent observations on primary human osteoclasts, suggesting a dysbalance between OBs and osteoclasts in favour of osteoclasts.
Herrmann
Markus
M
Department of Clinical Chemistry and Laboratory Medicine, University Hospital of Saarland, Homburg/Saar, Germany. markusherr@aol.com
Umanskaya
Natalia
N
Wildemann
Britt
B
Colaianni
Graziana
G
Widmann
Thomas
T
Zallone
Alberta
A
Herrmann
Wolfgang
W
D000135:Acid Phosphatase / Q000378:metabolism; D001857:Bone Matrix / Q000187:drug effects / Q000378:metabolism; D002113:Calcification, Physiologic / Q000187:drug effects; D002478:Cells, Cultured; D006710:Homocysteine / Q000494:pharmacology*; D006801:Humans; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects*; D015675:Osteocalcin / Q000378:metabolism; D010446:Peptide Fragments / Q000378:metabolism; D011347:Procollagen / Q000378:metabolism
D010446:Peptide Fragments; D011347:Procollagen; C047202:procollagen Type I N-terminal peptide; D006710:Homocysteine; D015675:Osteocalcin; D000135:Acid Phosphatase
Calcif Tissue Int. 2006 Sep;79(3):160-8
16969591
J Bone Miner Res. 2005 Jun;20(6):921-9
15883631
Biochim Biophys Acta. 2005 Apr 15;1740(1):12-6
15878736
Osteoporos Int. 2002 Jul;13(7):527-36
12111012
J Cell Biochem. 1999 Oct 1;75(1):22-35
10462701
Lancet. 2002 May 18;359(9319):1761-7
12049882
Clin Chem. 2007 Aug;53(8):1455-61
17586593
J Bone Miner Res. 2003 Jun;18(6):1139-41
12817771
J Bone Miner Res. 2007 Mar;22(3):465-75
17144789
Crit Rev Oral Biol Med. 1992;3(3):269-305
1571474
Osteoporos Int. 1997;7(1):1-6
9102057
J Cell Physiol. 1990 Jun;143(3):420-30
1694181
Bone. 2007 Oct;41(4):584-91
17681876
N Engl J Med. 2004 May 13;350(20):2033-41
15141041
Bone. 2006 Dec;39(6):1385-6; author reply 1386-7
16466975
Clin Chem Lab Med. 2005;43(10):1118-23
16197308
Bone. 2006 Sep;39(3):582-90
16644300
J Bone Miner Res. 2006 Jul;21(7):1003-11
16813521
Endocr Pract. 2003 Nov-Dec;9(6):544-64
14715483
JAMA. 2005 Mar 2;293(9):1082-8
15741530
Curr Opin Rheumatol. 2002 Jul;14(4):411-5
12118177
Osteoporos Int. 2002 Oct;13(10):765-7
12378364
J Bone Miner Res. 2004 Dec;19(12):1969-75
15537439
Osteoporos Int. 2005 Mar;16 Suppl 2:S8-S17
15378232
N Engl J Med. 2004 May 13;350(20):2042-9
15141042
Atherosclerosis. 2000 Oct;152(2):531-2
11203427
Endocr Rev. 1993 Aug;14(4):424-42
8223340
Clin Chem. 2005 Dec;51(12):2348-53
16195358
Osteoporos Int. 2004 Jun;15(6):439-46
15205714
Endocr Rev. 2000 Apr;21(2):115-37
10782361